Lancet Diabetes and Endocrinology, 7(12), 899-911. ELSEVIER SCIENCE INC McClung, M R, O'Donoghue, M L, Papapoulos, S E, Bone, H, Langdahl, B, Saag, K G, Reid, I R, Kiel, D P, Cavallari, I, Bonaca, M P, Wiviott, S D, de Villiers, T, Ling, X, Lippuner, K, Nakamura, T, Reginster, J Y, Rodriguez-Portales, J A, Roux, C, Zanchetta, J, Zerbini, C A F, Park, J G, Im, K A, Cange, A, Grip, L T, Heyden, N, DaSilva, C, Cohn, D, Massaad, R, Scott, B B, Verbruggen, N, Gurner, D, Miller, D L, Blair, M L, Polis, A B, Stoch, S A, Santora, A, Lombardi, A, Leung, A T, Kaufman, K D, Sabatine, M S & LOFT Investigators 2019, ' Odanacatib for the treatment of postmenopausal osteoporosis : results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study ', The Lancet Diabetes and Endocrinology, vol. 7, no. 12, pp. 899-911 . https://doi.org/10.1016/S2213-8587(19)30346-8